Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

A Perspective on Therapeutic Applications and Strategies to Mitigate Toxicity of Metallic Nanoparticles

Author(s): Arjunan Karuppaiah*, Divakar Selvaraj, Mohan Sellappan, Arumugam Nagarajan, Dinesh Babu, Habibur Rahman, Thiagarajan Madheswaran, Bharadhan Bose and Tamilselvan Natrajan

Volume 29, Issue 4, 2023

Published on: 13 January, 2023

Page: [239 - 245] Pages: 7

DOI: 10.2174/1381612829666230109111635

Price: $65

Abstract

Metallic nanoparticles (MNPs) have been widely used for diagnostic and therapeutic purposes in clinical practice. A number of MNP formulations are being investigated in clinical trials for various applications. This increase in the use of NPs results in higher exposure to humans, leading to toxicity issues. Hence, it is necessary to determine the possible undesirable effects of the MNPs after in-vivo application and exposure. One of the main reasons for the toxicity of MNPs is the release of their respective metallic ions throughout the body. Many research studies are in progress investigating the various strategies to reduce the toxicity of MNPs. These research studies aim to change the size, dose, agglomeration, release, and excretion rates of MNPs. In this perspective review, we discussed the possible strategies to improve the therapeutic effects of MNPs through various processes, with lessons learned from the studies involving silver nanoparticles (AgNPs). We also discussed the ways to manage the toxicity of MNPs by purification, surface functionalization, synergistic effect, and targeted therapy approach. All these strategies could reduce the dose of the MNPs without compromising their therapeutic benefits, which could decrease the toxicity of MNPs. Additionally, we briefly discussed the market and toxicology testing for FDA-regulated MNPs.

Next »
[1]
Karuppaiah A, Siram K, Selvaraj D, Ramasamy M, Babu D, Sankar V. Synergistic and enhanced anticancer effect of a facile surface modified non-cytotoxic silver nanoparticle conjugated with gemcitabine in metastatic breast cancer cells. Mater Today Commun 2020; 23: 100884.
[http://dx.doi.org/10.1016/j.mtcomm.2019.100884]
[2]
Maduray K, Parboosing R. Metal nanoparticles: A promising treatment for viral and arboviral infections. Biol Trace Elem Res 2021; 199(8): 3159-76.
[http://dx.doi.org/10.1007/s12011-020-02414-2] [PMID: 33029761]
[3]
Moodley J, Babu Naidu Krishna S, Pillay K, Govender P. Green synthesis of metal nanoparticles for antimicrobial activity. Novel Nanomaterials. IntechOpen 2021.
[http://dx.doi.org/10.5772/intechopen.94348]
[4]
Mazayen ZM, Ghoneim AM, Elbatanony RS, Basalious EB, Bendas ER. Pharmaceutical nanotechnology: From the bench to the market. Future J Pharm Sci 2022; 8(1): 12.
[http://dx.doi.org/10.1186/s43094-022-00400-0] [PMID: 35071609]
[5]
Karuppiah A, Rajan R, Ramanathan M, Nagarajan A. Cytotoxicity and synergistic effect of biogenically synthesized ternary therapeutic nano conjugates comprising plant active principle, silver and anticancer drug on MDA-MB-453 breast cancer cell line. Asian Pac J Cancer Prev 2020; 21(1): 195-204.
[http://dx.doi.org/10.31557/APJCP.2020.21.1.195] [PMID: 31983184]
[6]
Chouhan RS, Horvat M, Ahmed J, Alhokbany N, Alshehri SM, Gandhi S. Magnetic nanoparticles-a multifunctional potential agent for diagnosis and therapy. Cancers 2021; 13(9): 2213.
[http://dx.doi.org/10.3390/cancers13092213] [PMID: 34062991]
[7]
Metal Nanoparticles Market by metal (Platinum, Gold, Silver, Iron, Titanium, Copper, Nickel), End-use industry (Pharmaceutical & healthcare, Electrical & electronics, Catalyst, Personal care & cosmetics), and Region - Global Forecast to 2022. 2022. Available from: http://ak007.over-blog.com/2019/05/metal-nanoparti- cles-market-to-be-worth-25.26-billion-usd-by-2022.html
[8]
Xu L, Dan M, Shao A, et al. Silver nanoparticles induce tight junction disruption and astrocyte neurotoxicity in a rat blood-brain barrier primary triple coculture model. Int J Nanomedicine 2015; 10: 6105-18.
[PMID: 26491287]
[9]
Sengul AB, Asmatulu E. Toxicity of metal and metal oxide nanoparticles: A review. Environ Chem Lett 2020; 18(5): 1659-83.
[http://dx.doi.org/10.1007/s10311-020-01033-6]
[10]
Karuppaiah A, Rajan R, Hariharan S, Balasubramaniam DK, Gregory M, Sankar V. Synthesis and characterization of folic acid conjugated gemcitabine tethered silver nanoparticles (FA-GEM-AgNPs) for targeted delivery. Curr Pharm Des 2020; 26(26): 3141-6.
[http://dx.doi.org/10.2174/1381612826666200316143239] [PMID: 32175835]
[11]
Długosz O, Szostak K, Staroń A, Pulit-Prociak J, Banach M. Methods for reducing the toxicity of metal and metal oxide NPs as biomedicine. Materials 2020; 13(2): 279.
[http://dx.doi.org/10.3390/ma13020279] [PMID: 31936311]
[12]
Ferdous Z, Nemmar A. Health impact of silver nanoparticles: A review of the biodistribution and toxicity following various routes of exposure. Int J Mol Sci 2020; 21(7): 2375.
[http://dx.doi.org/10.3390/ijms21072375] [PMID: 32235542]
[13]
Gliga AR, Skoglund S, Odnevall Wallinder I, Fadeel B, Karlsson HL. Size-dependent cytotoxicity of silver nanoparticles in human lung cells: The role of cellular uptake, agglomeration and Ag release. Part Fibre Toxicol 2014; 11(1): 11.
[http://dx.doi.org/10.1186/1743-8977-11-11] [PMID: 24529161]
[14]
Karlsson HL, Toprak MS, Fadeel B. Toxicity of Metal and Metal Oxide Nanoparticles. Handb Toxicol Met. Elsevier: Amsterdam, 2015; pp. 75-112.
[15]
Karuppaiah A, Babu D, Selvaraj D, et al. Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats. Eur J Pharm Sci 2021; 165: 105938.
[http://dx.doi.org/10.1016/j.ejps.2021.105938] [PMID: 34256103]
[16]
Xu X, Cölfen H. Ultracentrifugation techniques for the ordering of nanoparticles. Nanomaterials 2021; 11(2): 333.
[http://dx.doi.org/10.3390/nano11020333] [PMID: 33513966]
[17]
Krishnamoorthy K, Mahalingam M. Selection of a suitable method for the preparation of polymeric nanoparticles: Multi-criteria decision making approach. Adv Pharm Bull 2015; 5(1): 57-67.
[PMID: 25789220]
[18]
Weingart J, Vabbilisetty P, Sun XL. Membrane mimetic surface functionalization of nanoparticles: Methods and applications. Adv Colloid Interface Sci 2013; 197-198: 68-84.
[http://dx.doi.org/10.1016/j.cis.2013.04.003] [PMID: 23688632]
[19]
Ungor D, Dékány I, Csapó E. Reduction of Tetrachloroaurate(III) ions with bioligands: Role of the thiol and amine functional groups on the structure and optical features of gold nanohybrid systems. Nanomaterials 2019; 9(9): 1229.
[http://dx.doi.org/10.3390/nano9091229] [PMID: 31470660]
[20]
Unsoy G, Yalcin S, Khodadust R, Mutlu P, Onguru O, Gunduz U. Chitosan magnetic nanoparticles for pH responsive Bortezomib release in cancer therapy. Biomed Pharmacother 2014; 68(5): 641-8.
[http://dx.doi.org/10.1016/j.biopha.2014.04.003] [PMID: 24880680]
[21]
Dias AMGC, Hussain A, Marcos AS, Roque ACA. A biotechnological perspective on the application of iron oxide magnetic colloids modified with polysaccharides. Biotechnol Adv 2011; 29(1): 142-55.
[http://dx.doi.org/10.1016/j.biotechadv.2010.10.003] [PMID: 20959138]
[22]
Işıklan N, Polat S. Synthesis and characterization of thermo/pH-sensitive pectin-graft-poly(dimethylaminoethyl methacrylate) coated magnetic nanoparticles. Int J Biol Macromol 2020; 164: 4499-515.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.09.002] [PMID: 32898537]
[23]
National Center for Toxicological Research Nanotechnology Programs Available from: https://www.fda.gov/science-research/nanotechnology-programs-fda/national-center-toxicological-research-nanotechnology-programs

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy